Prolactin

 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, Xerostomia, SIRS, Schizophrenia, Xanomeline, Dizziness, Glycated hemoglobin, Extrapyramidal symptoms, Weight gain, Patient, Syndrome, Constipation, Diarrhea, Bristol Myers Squibb, MD, Nature, Congress, Indigestion, Nausea, Prolactin, Safety, Vomiting, BMI, Schizophrenia International Research Society, Hypertension, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
  • “These long-term safety results and metabolic outcomes from the EMERGENT program are extremely encouraging, allowing us to further understand the tolerability profile of KarXT in people living with schizophrenia,” said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb.
  • In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on key metabolic parameters over 52 weeks of treatment.
  • In the long-term studies, KarXT was generally well-tolerated across 52 weeks of treatment, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, SIRS, Schizophrenia, Xanomeline, Assessment, Patient, Bristol Myers Squibb, MD, Positive, Efficacy, Congress, Prolactin, Clinical trial, Safety, PANSS, FDA, Schizophrenia International Research Society, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia.
  • Long-term efficacy data from the trial were presented in a poster titled, “Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia” (Poster F264) at the Annual Congress of the Schizophrenia International Research Society (SIRS) being held April 3-7, 2024, in Florence, Italy.
  • In the interim analysis, KarXT was associated with significant improvement in symptoms of schizophrenia across all efficacy measures at 52 weeks.
  • In long-term trials, KarXT was generally well tolerated, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Retrieved on: 
Friday, December 22, 2023
Neurology, Biotechnology, Pharmaceutical, General Health, Health, FDA, Mental Health, Clinical Trials, Akathisia, BMY, Conference, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Treatment, Drug development, Extrapyramidal symptoms, PRTC, Psychiatry, Bipolar I disorder, Acquisition, PDUFA, Psychosis, Conference call, NDA, KRTX, Prolactin, Citigroup, Therapy, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • ET
    PRINCETON, N.J. & BOSTON -- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Akathisia, BMY, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Drug development, Extrapyramidal symptoms, Psychiatry, Bipolar I disorder, FDA, Acquisition, PDUFA, Psychosis, NDA, KRTX, Prolactin, Citigroup, Therapy, Schizophrenia, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Akathisia, BMY, Cognition, Food, Bristol Myers Squibb, Simpson Thacher & Bartlett, Multimedia, Drug development, Extrapyramidal symptoms, Psychiatry, Bipolar I disorder, FDA, Acquisition, PDUFA, Psychosis, NDA, KRTX, Prolactin, Citigroup, Therapy, Schizophrenia, Covington & Burling, M1, Goldman Sachs, Weight gain, Growth, Webcast, Patient, Safety, M4, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Women-owned Startups Collaborate Toward a Scalable and Cost-Effective Future for Sustainable Biotechnology

Retrieved on: 
Thursday, October 26, 2023
Science, Genetic distance, Health, Research Triangle Park, Biotechnology, Carbon, Triangle Park (Quezon City), Milk, Protein, Infant formula, Growth, A-DNA, Alexandria Center of Arts, Plant, Tiamat, Breast milk, Prolactin, Hormone, Woman, Regenerative medicine, Lactation, Fine chemical, Dairy

By leveraging the potential of human mammary cells, BIOMILQ can bring more of the functional benefits of breast milk to more babies.

Key Points: 
  • By leveraging the potential of human mammary cells, BIOMILQ can bring more of the functional benefits of breast milk to more babies.
  • BIOMILQ and Tiamat Sciences are both headquartered in the Alexandria Center for AgTech – Research Triangle Park, a hub for emerging and global agtech companies.
  • In three months, Tiamat Sciences successfully produced Human Prolactin, a vital biomolecule for lactation, using an entirely animal-free production process.
  • BIOMILQ is a women-owned and science-led mammary biotechnology start-up leveraging its patented technology to produce functional cell-cultured human milk components outside of the body.

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

Retrieved on: 
Wednesday, August 30, 2023
Biotechnology, Health, Clinical Trials, ACCP, American College of Clinical Pharmacology, Development of the human body, DSM-IV codes, Medication, Plasma, Pharmacokinetics, Annual general meeting, IEC, Prolactin, Seizure, American College, QEEG, Pharmaceutical industry, Safety, Pharmacology

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.
  • Title: The PACIFIC Study: A Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758)
    Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist (#754)
    Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)
    Title: A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement (#060)

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Retrieved on: 
Tuesday, August 8, 2023
Anticonvulsant, GABA, Prolactin, AED, CSE, Psychosis, Quantitative electroencephalography, Food and Drug Administration, Pharmacokinetics, Neuroscience, Doctor of Philosophy, DSM-IV codes, Plasma, EEG, Master of Science, FDA, Epilepsy, Addiction, Food, Safety, Pharmaceutical industry, Dietary supplement

-- Company to host webcast to discuss findings of the Phase 1 study today, August 8, 2023, at 4:30pm ET

Key Points: 
  • Central target engagement, as the treatment group was easily identified in blinded data using qEEG power signature.
  • “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate.
  • The Phase 1 study was conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies.
  • The study evaluated the safety, tolerability, pharmacokinetic (PK), and food effect of BMB-101 in healthy volunteers.

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Retrieved on: 
Thursday, July 20, 2023
Prolactin, CSE, Psychosis, Quantitative electroencephalography, Pharmacokinetics, DSM-IV codes, Plasma, Addiction, Patient, Drug discovery, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced the successful completion of its three-part Phase 1 study of BMB-101. The study, conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies, evaluated the safety, tolerability, pharmacokinetic (PK), and food effect in healthy volunteers.

Key Points: 
  • BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders.
  • The current formulation allows for twice-a-day oral dosing, and with further formulation development, there may be potential for once-a-day dosing.
  • BMB-101 is now a Phase 2 ready asset, and we look forward to sharing our further progress,” stated Ian McDonald, CEO of Bright Minds.
  • The Company is currently awaiting the qEEG (Quantitative Electroencephalogram) data and will provide a more detailed discussion of the Phase 1 results when available.

Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Plasma, Safety, Insurance, Longboard, SLC6A1 epileptic encephalopathy, SAD, Clinical trial, Medication, CNS, DSM-IV codes, Cerebrospinal fluid, Graduate School of Asia-Pacific Studies, Quantitative electroencephalography, PK, PIN, Research, Agonist, Prolactin, Investment, Pharmacology, Trial of the century, PD, Seizure, FINANCIAL, Pharmaceutical industry, Dietary supplement, Health care, Cryptocurrency

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2022.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2022.
  • LP352 is the only 5-HT2C receptor agonist being dose optimized for developmental and epileptic encephalopathies (DEEs).
  • FULL YEAR 2022 FINANCIAL RESULTS:
    At December 31, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $67.6 million.
  • ET to discuss 2022 financial results and provide a corporate update.